Biotech and Pharma Industry News | BioPharma Dive
网页Moderna to cut costs, trim pipeline in R&D revamp. As part of a broad restructuring, the company plans to reduce research spending by 20% over the next few years and ax five programs in early development. It won’t cut jobs, however, a …
4D Molecular data ‘bode well’ for eye gene therapy, but shares fall
网页2 天之前 · Dive Insight: 4D Molecular is one of a handful of developers testing genetic treatments for conditions of the eye. Seven years ago, the field produced the first gene therapy approved in the U.S. for an inherited disease, Spark Therapeutics’ Luxturna. But progress has been rockier since then, despite periodic investments by large pharmaceutical companies in biotechs like Spark that have ...
As Biosecure bill advances, drugmakers prepare for prospect of …
网页5 天之前 · To some, any contract with a Chinese firm could be a risk. Liver and cardiometabolic-focused biotech 89bio, which contracted with China’s BiBo Biopharma Engineering to build a plant for production of its MASH drug earlier this year, has said it’s “exposed to the possibility of product supply disruption and increased costs” as a result of the Biosecure Act.
Gene therapy startup emerges with green light for first-of-its-kind ...
网页2024年9月12日 · The company licensed its core technology, dubbed TransJoin, from Nationwide Children’s Hospital in Columbus, Ohio, a leading hub for gene therapy research. Nationwide’s Timothy Cripes, a pediatric division chief, led work on the technology that was published in Science Advances in 2022. Cripes is one of the company’s founders, along with Brian Kaspar — the scientific founder of the ...
GSK antibody drug reduces COPD attacks in trial | BioPharma Dive
网页2024年9月6日 · Dive Brief: GSK on Friday said its Nucala medicine succeeded in a Phase 3 study of patients with chronic obstructive pulmonary disease, offering the British drugmaker another shot at an expanded approval for the drug; The trial, known as MATINEE, included COPD patients suffering from chronic bronchitis and/or emphysema who were already taking inhaled therapies and showed evidence of a certain ...
Pharma News | BioPharma Dive
网页2024年9月13日 · Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise. OrsoBio is advancing several weight loss medicines. Elsewhere, Boehringer Ingelheim pushed forward with a geographic atrophy drug and Vaxcyte raised $1.3 billion. By BioPharma Dive staff • Sept. 6, 2024. Access now .
Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in …
网页2024年9月13日 · A twice-yearly HIV shot developed by Gilead reduced the risk of infection by 96% compared to background disease incidence, the company said Thursday. The finding comes from a Phase 3 trial of nearly 2,200 cisgender men and gender-diverse people, and follows the success of another late-stage study in June. As a result, Gilead has stopped the blinded portion of the trial and will "work urgently ...
First look at Verve study data offers base editing ‘proof of principle’
网页2023年11月12日 · Three million adults in the U.S. and Europe are estimated to have HeFH, according to Verve. Among three participants given the two highest tested doses, treatment with Verve’s therapy lowered LDL cholesterol levels by 39%, 48% and 55% compared to the study’s start. PCSK9 levels were also dramatically reduced, by …
Biotech News - BioPharma Dive
网页2024年9月13日 · ArsenalBio raises $325M in one of the year’s largest biotech funding rounds. The financing comes amid a slowdown in venture investment for gene and cell therapy startups, and will support multiple solid tumor programs. By Gwendolyn Wu • Sept. 4, 2024. News roundup.
Deep Dive - BioPharma Dive
网页2024年6月27日 · A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology. Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. Jonathan Gardner • Sept. 4 ...
跳至内容